Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifasutenizol in H. Pylori Infection
NCT05857163Phase 3Completed
- Sponsor
- TenNor Therapeutics
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rifasutenizol in Helicobacter pylori infection (2 arms), sponsored by TenNor Therapeutics. Primary endpoint: Eradication Rate of H.Pylori Infection. Started May 2023; status: completed.
02
Drugs
rifasutenizol
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05857163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05857163.